Phospholipid phosphatase 7 (PLPP7)

Phospholipid phosphatase 7 (PLPP7) is a transmembrane protein of the nuclear envelope, classified as part of the phosphatidic acid phosphatase type 2 domain-containing family, but is considered catalytically inactive. Despite sequence similarity to lipid phosphatases, PLPP7 has no detectable enzymatic activity. It plays an important role in muscle by acting as a negative regulator of muscle cell differentiation, partly via effects on mTOR signaling. It is implicated in the organization of the muscle genome by controlling the positioning of genes at the nuclear envelope—a process important for gene expression regulation in muscle cells. Mutations or reduced expression of PLPP7, as observed in certain muscular dystrophies and myotonic dystrophy type 1, are associated with muscle pathology. PLPP7 is also known as NET39, reflecting its prominent function as a nuclear envelope transmembrane protein in muscle tissue[1][2][3][4][5][8]. No clinically approved drugs are known to directly target PLPP7, and the protein is not currently considered a practical therapeutic target but is of research interest for understanding nuclear architecture and muscle disease.

Other names

C9orf67PPAPDC3MGC12921FLJ14662NET39Phosphatidic acid phosphatase type 2 domain-containing protein 3nuclear envelope transmembrane protein NET39probable lipid phosphate phosphatase PPAPDC3epididymis secretory sperm binding protein